article thumbnail

FDA Approves Susvimo for Diabetic Macular Edema

Drugs.com

Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic. WEDNESDAY, Feb. 5, 2025 -- The U.S.

article thumbnail

Customer Success: How do we identify generic entrants before they get FDA approval?

Drug Patent Watch

The post Customer Success: How do we identify generic entrants before they get FDA approval? DrugPatentWatch can help identify generic entrants at the earliest stages Many clients come to DrugPatentWatch seeking to identify generic entrants well before they launch. CDMOs, equipment manufacturers, regulatory consultants, and….

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

BioPharma Drive: Drug Pricing

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

article thumbnail

Madrigal wins FDA approval of first drug for MASH

BioPharma Drive: Drug Pricing

Rezdiffra’s clearance is a turning point in the fight against the liver disease. But its sales potential is unclear, and competition could emerge from popular weight loss drugs.

article thumbnail

FDA Approves Journavx, First New Non-Opioid Pain Pill in Decades

Drugs.com

Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin. FRIDAY, Jan. 31, 2025 -- The U.S. The new pill, developed by Vertex.

article thumbnail

FDA Approves Wearable Infusion Device for Advanced Parkinson Disease

Drugs.com

Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with. THURSDAY, Feb. 6, 2025 -- The U.S.

article thumbnail

FDA Approved Oncology Drugs 2023

Crown Bioscience

In a significant development, the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs in 2023. This marks the second-highest count in the past 30 years, with the highest being 59 new drug approvals in 2018 and represents an impressive 50% increase in drugs approved in 2022.